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our omaunes for radiofrequenq catheter ahfation in infants and small 
cbddm continue to show a 90% &cacy, with no major compkations 
reported. 
We believe that there is a morbidity and mortahty, albeit sn8ail. 
from the medical management of supraventricular tacbycardir in 
fnfancy and cbifdbood. At the Medical University of South Carolina, 
we have used aggmmhe pharmacologic and nonphamacologic tber- 
apy in infancy and belii the two approaches are compfementaty and 
not competitive. AJtbougb viewpoints on the proper management of 
this entity are diverse it is important for us all to have a precise 
understanding of approaches that are divergent from our own. 
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Are tbe Drug Names Coumadin and 
Warfhrin Interchangeable? 
Nutnemus artidea pub&bed m several dit7erent journak over the past 
few years have negkted to capitafixe the letter “c” in Coumadin. a 
brand name of warfarin sodium manufadured hy Du Pont Pharma. 
ExamplesolthisourbefwmliocardiwascYlar(1-9,15-17),induding 
the Journal (136). as well as noncardmmmmar puhbshed reports 
(10-14). Although style fq4Tdkah for many of these journak 
dktatetbatdmgsbereferredtobytbeirgenericnames,theword 
“wumadin” often appears witbout reference to ?varfarin.” In one 
~theterm”ammadinderivatiwYisused(2).IsCotmtadm 
nowa~drug?lstheresuchathingasa“~m~derivative?” 
To cite some of the more recent examples, in the September 1995 
~oftheJoumalWcngetal.(l)evaluatedtbesafetyandefficacy 
ofPatmax-Schatxstentin@ntationiosapbenousveingraftlesioos.In 
that study, stent impbtation was followd by treatment with ‘km- 
mrnfinandd@r&mok.“fntbeApril1994issueoftheJoornaf,a 
stlQby+lisonetaf.(3)addmmedtfmtssneofusingpercotaneous 
ba&mmaiangiop~ofmpbmumswingraftfesJonsinpatients 
witbme4kdyrefmcto4yImsIaNeangina.Illtbestudyabstrad, 
;bciiuoctive~b$ctberaWconsistedot,amoogotlterdntgs, 
“wumadfn.” Hossever, iu the me- ‘+wahrs is lisled as 
"djunaivepbarmaccthe~~.WOUldtbiSiIllpIyfJUitcoumadin~ 
uaedexcGmly~tbmesmdics,oranddotherbrandsof 
W8IfXkIbavebeenUR?daSWdI?pubiisbedreportsOftheAPRJCOT 
~~~~,~~. *tb the original -eY coolpariop 
Toutndm (4)+andarmbquentIettertotbeeditor(5) 
andangiogmpbicanalysk(6)referringtoacompakmbehveen 
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Wby should practitioners Gtre about the semantics of “warfarin” 
versus ‘Coumadim?” In studii performed in the United States, 
“coumadin” is most IibeIy to be Coumadm because Du Pont Pbarma 
is currently the sole manufacturer of warfarin sodium in the United 
States. However, other brands of warfarin, for example, Panwar6n 
(warfarin sodium, Abbott Laboratories) and Sofarfn (warfarin potas- 
sium, Lemmon Company) were distributed in the United States until 
approximately 1990. Other countries have different brands of warfarin 
available as well, such as War&me (Frosst, Canada) and Waran 
(Nycomed, Norway). In the United Ringdom, until early 1995, two 
different companies bad heen manufactming warfarim Roebringer 
Ingelheim (Warfarin) and Goldshield (Marevan). fn addition, Couma- 
din is not the only available oral anticoagulant in the United States 
Dicumarol, another coumarin derivative, and anisindione (Miradon), 
an indandione derivative, are also available. 
Is thii to say that conclusions made regarding Coumadin cannot he 
extended to other brands of warfarin? Different oral anticoagulants 
have different pharmacologic properties, and difierent brands of 
warfarin may have ditfeting pbarmacokmetic variabks that may at&t 
indiidual patient response. For example, bioavaifability in individual 
subjects has been found to dither as much as 27% between brands of 
warfarin (IS). Therefore, clinical study results and application to 
practice may he atkcted by the type of oral anticoagtdant or brand of 
warfarin selected. As a more standardii measure of warfarin effq 
the target Jntemational Norma&d Ratios (WRs) and achieved fNRs 
should be reported in clinical research studies to better permit 
practitioners to apply dmical research rest& in tbeii patients. Wben 
matting reference to Coumadiq at a miniium, the first letter of the 
trade name should he capitalixed. Some editors may also use Comna- 
dma. The use of the term ‘warfarin” may be more appropriate in 
documents such as review articles and letters to the editor. which deaf 
with warfarin but are not specik for the Qumadin brand. 
Many authors and editors may continue to mabe the “coumadm” 
error because the word “Comnadio” has entered our daily conversa- 
tion about oral anticoagulation in a manner analogous to Kleenex 
facial tissues or Xerox photocopies. We even speab ahout “Cmmadi- 
nixing” patients. However, in the professional format of published 
medical reports, partktdarly in cardiovascular journals, we sboufd 
strive for accuracy in drug descriptions. The words “Coumadm” and 
“warfarin” are net necessarily interchangeable. 
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